AR081364A1 - Composiciones farmaceuticas de pazopanib y metodos para su elaboracion - Google Patents
Composiciones farmaceuticas de pazopanib y metodos para su elaboracionInfo
- Publication number
- AR081364A1 AR081364A1 ARP110101514A ARP110101514A AR081364A1 AR 081364 A1 AR081364 A1 AR 081364A1 AR P110101514 A ARP110101514 A AR P110101514A AR P110101514 A ARP110101514 A AR P110101514A AR 081364 A1 AR081364 A1 AR 081364A1
- Authority
- AR
- Argentina
- Prior art keywords
- pazopanib
- solution
- modified cyclodextrin
- milligrams
- milliliter
- Prior art date
Links
- 239000003798 L01XE11 - Pazopanib Substances 0.000 title abstract 12
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical group C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 title abstract 12
- 229960000639 pazopanib Drugs 0.000 title abstract 12
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 5
- 239000000203 mixture Substances 0.000 abstract 4
- 239000002253 acid Substances 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 239000012047 saturated solution Substances 0.000 abstract 3
- 239000000243 solution Substances 0.000 abstract 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 2
- 239000012458 free base Substances 0.000 abstract 2
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003002 pH adjusting agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Reivindicacion 1: Una composicion farmacéutica, la cual comprende: una cantidad de una sal de adicion de ácido de pazopanib equivalente a aproximadamente 10 miligramos de base libre de pazopanib/mililitro de la composicion; de aproximadamente el 2.0 a aproximadamente el 13.0 por ciento en peso/peso de una ciclodextrina modificada que es adecuada para utilizarse en una formulacion oftálmica, seleccionándose la ciclodextrina modificada de tal manera que la ciclodextrina modificada dé como resultado la pKa de pazopanib en una solucion de 10 miligramos de pazopanib/mililitro de agua con una cantidad dada de ciclodextrina modificada que sea más baja que la pKa de pazopanib en una solucion de 10 miligramos de pazopanib/mililitro de agua; si es necesario, un agente de ajuste del pH para proporcionar un pH de 3.5 a 5.7; si es necesario, un agente de ajuste de tonicidad para proporcionar una osmolaridad de 200 a 400 mOsm; y agua; en donde la composicion es estable durante cuando menos 2 meses. Reivindicacion 38: Un método para la preparacion de una solucion super- saturada de pazopanib, comprendiendo este método: 5 formar una solucion acuosa de una sal de adicion de ácido de pazopanib y una ciclodextrina modificada adecuada para utilizarse en una formulacion oftálmica; y ajustar el pH de la solucion entre 3.5 a 5.7, para obtener una solucion super-saturada de pazopanib, en donde la lo concentracion de la sal de adicion de ácido de pazopanib solubilizada en la solucion super-saturada es equivalente a aproximadamente 10 miligramos/mililitro de la base libre de pazopanib.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33171510P | 2010-05-05 | 2010-05-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR081364A1 true AR081364A1 (es) | 2012-08-29 |
Family
ID=44851507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110101514A AR081364A1 (es) | 2010-05-05 | 2011-05-03 | Composiciones farmaceuticas de pazopanib y metodos para su elaboracion |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20110281901A1 (es) |
| EP (1) | EP2566331B1 (es) |
| JP (1) | JP5835717B2 (es) |
| KR (1) | KR20130071434A (es) |
| CN (1) | CN102970871A (es) |
| AR (1) | AR081364A1 (es) |
| AU (1) | AU2011247995B2 (es) |
| BR (1) | BR112012028291A2 (es) |
| CA (1) | CA2798386A1 (es) |
| CL (1) | CL2012003075A1 (es) |
| CO (1) | CO6640262A2 (es) |
| CR (1) | CR20120556A (es) |
| DO (1) | DOP2012000281A (es) |
| EA (1) | EA201291168A1 (es) |
| ES (1) | ES2519615T3 (es) |
| IL (1) | IL222751A0 (es) |
| MA (1) | MA34286B1 (es) |
| MX (1) | MX2012012837A (es) |
| NZ (1) | NZ603411A (es) |
| PE (1) | PE20130217A1 (es) |
| PH (1) | PH12012502159A1 (es) |
| SG (1) | SG185087A1 (es) |
| TW (1) | TW201206908A (es) |
| UY (1) | UY33367A (es) |
| WO (1) | WO2011140343A1 (es) |
| ZA (1) | ZA201208265B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| US12370352B2 (en) | 2007-06-28 | 2025-07-29 | Cydex Pharmaceuticals, Inc. | Nasal and ophthalmic delivery of aqueous corticosteroid solutions |
| ES2493641T3 (es) * | 2007-06-28 | 2014-09-12 | Cydex Pharmaceuticals, Inc. | Administración nasal de soluciones acuosas de corticosteroides |
| US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
| UY33367A (es) * | 2010-05-05 | 2011-10-31 | Glaxo Wellcome Mfg Pte Ltd | Composiciones farmacéuticas y métodos para su elaboración |
| SI2600930T1 (sl) | 2010-08-05 | 2021-08-31 | Forsight Vision4, Inc. | Injekcijska naprava za dajanje zdravila |
| AU2011329656B2 (en) | 2010-11-19 | 2017-01-05 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
| EP2739252A4 (en) | 2011-08-05 | 2015-08-12 | Forsight Vision4 Inc | DISPOSAL OF SMALL MOLECULES THROUGH AN IMPLANTABLE THERAPEUTIC DEVICE |
| ES3049671T3 (en) | 2011-09-16 | 2025-12-17 | Forsight Vision4 Inc | Fluid exchange apparatus |
| CN104244952A (zh) * | 2012-02-17 | 2014-12-24 | 药品循环公司 | 组蛋白脱乙酰酶抑制剂与帕唑帕尼的组合及其用途 |
| CN104160762B (zh) * | 2012-03-08 | 2019-03-15 | 三星电子株式会社 | 用于控制无线通信系统中的服务的方法 |
| US9968603B2 (en) | 2013-03-14 | 2018-05-15 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
| AU2014241163B2 (en) | 2013-03-28 | 2018-09-27 | Forsight Vision4, Inc. | Ophthalmic implant for delivering therapeutic substances |
| DK3039424T3 (da) | 2013-08-28 | 2020-08-31 | Crown Bioscience Inc Taicang | Genekspressionssignaturer, der er prædiktive for et individs respons på en multikinaseinhibitor, og fremgangsmåder til anvendelse af disse |
| CA2957548A1 (en) * | 2014-08-08 | 2016-02-11 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
| SG11201703726XA (en) | 2014-11-10 | 2017-06-29 | Forsight Vision4 Inc | Expandable drug delivery devices and method of use |
| JP6818264B2 (ja) | 2014-12-25 | 2021-01-20 | 国立大学法人京都大学 | 高密度リポタンパク質およびその細胞親和性ペプチドを融合した高密度リポタンパク質の点眼による後眼部薬物デリバリー |
| MX2018012021A (es) | 2016-04-05 | 2019-01-24 | Forsight Vision4 Inc | Dispositivos de administracion de farmacos oculares implantables. |
| WO2018192416A1 (en) * | 2017-04-17 | 2018-10-25 | National Institute Of Biological Sciences, Beijing | Treating Male Senescence |
| US11174253B2 (en) | 2017-08-02 | 2021-11-16 | Alphala Co., Ltd. | Compound and pharmaceutical composition containing the same |
| PT3810089T (pt) * | 2018-06-07 | 2023-08-23 | Pfizer | Formulação aquosa compreendendo 1-(4-{[4- (dimetilamino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6- dimorfolin-4-il-1,3,5-triazin-2-il)fenil]ureia |
| CN113350351A (zh) * | 2020-03-13 | 2021-09-07 | 青晓制药公司 | 帕唑帕尼的应用、药物组合物、注射液及制备方法和应用 |
| USD1033637S1 (en) | 2022-01-24 | 2024-07-02 | Forsight Vision4, Inc. | Fluid exchange device |
| US20240050429A1 (en) * | 2022-08-10 | 2024-02-15 | Qx Therapeutics, Inc. | Pazopanib pharmaceutical composition, injection and preparation method and use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8904296D0 (sv) * | 1989-12-21 | 1989-12-21 | Pharmacia Ab | Transdermal system |
| US7893040B2 (en) * | 2005-07-22 | 2011-02-22 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
| BRPI0619057A2 (pt) * | 2005-11-29 | 2011-09-20 | Smithkline Beecham Corp | formulação farmacêutica de uso tópico, uso de um ou mais compostos, e, compostos |
| AR059066A1 (es) * | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| CA2649779A1 (en) * | 2006-04-18 | 2007-10-25 | Ekr Therapeutics, Inc. | Pre-mixed, ready-to-use iv bolus compositions and methods of use |
| MX2010004281A (es) * | 2007-10-19 | 2010-09-10 | Sarcode Corp | Composiciones y metodos para el tratamiento de la retinopatia diabetica. |
| ES2494365T3 (es) * | 2008-01-30 | 2014-09-15 | Genentech, Inc. | Compuestos de pirazolopirimidina que inhiben PI3K y métodos de uso |
| MX2012000706A (es) * | 2009-07-16 | 2012-06-01 | Glaxo Wellcome Mfg Pte Ltd | Metodo de tratamiento. |
| US20120232102A1 (en) * | 2009-09-30 | 2012-09-13 | Chun-Fang Xu | Methods Of Administration And Treatment |
| TW201201808A (en) * | 2010-01-06 | 2012-01-16 | Glaxo Wellcome Mfg Pte Ltd | Treatment method |
| US20130023550A1 (en) * | 2010-05-05 | 2013-01-24 | Glaxo Wellcome Manufacturing Pte, Ltd | Pharmaceutical compositions and methods of making same |
| UY33367A (es) * | 2010-05-05 | 2011-10-31 | Glaxo Wellcome Mfg Pte Ltd | Composiciones farmacéuticas y métodos para su elaboración |
-
2011
- 2011-05-03 UY UY0001033367A patent/UY33367A/es unknown
- 2011-05-03 AR ARP110101514A patent/AR081364A1/es unknown
- 2011-05-03 TW TW100115488A patent/TW201206908A/zh unknown
- 2011-05-05 CN CN2011800333447A patent/CN102970871A/zh active Pending
- 2011-05-05 NZ NZ603411A patent/NZ603411A/en not_active IP Right Cessation
- 2011-05-05 EP EP11778348.0A patent/EP2566331B1/en active Active
- 2011-05-05 PH PH1/2012/502159A patent/PH12012502159A1/en unknown
- 2011-05-05 WO PCT/US2011/035363 patent/WO2011140343A1/en not_active Ceased
- 2011-05-05 BR BR112012028291A patent/BR112012028291A2/pt not_active IP Right Cessation
- 2011-05-05 AU AU2011247995A patent/AU2011247995B2/en not_active Ceased
- 2011-05-05 KR KR1020127031739A patent/KR20130071434A/ko not_active Withdrawn
- 2011-05-05 PE PE2012002115A patent/PE20130217A1/es not_active Application Discontinuation
- 2011-05-05 US US13/101,689 patent/US20110281901A1/en not_active Abandoned
- 2011-05-05 JP JP2013509268A patent/JP5835717B2/ja not_active Expired - Fee Related
- 2011-05-05 CA CA2798386A patent/CA2798386A1/en not_active Abandoned
- 2011-05-05 EA EA201291168A patent/EA201291168A1/ru unknown
- 2011-05-05 MX MX2012012837A patent/MX2012012837A/es active IP Right Grant
- 2011-05-05 SG SG2012079968A patent/SG185087A1/en unknown
- 2011-05-05 MA MA35417A patent/MA34286B1/fr unknown
- 2011-05-05 US US13/133,030 patent/US20120028918A1/en not_active Abandoned
- 2011-05-05 ES ES11778348.0T patent/ES2519615T3/es active Active
-
2012
- 2012-10-29 IL IL222751A patent/IL222751A0/en unknown
- 2012-10-31 CL CL2012003075A patent/CL2012003075A1/es unknown
- 2012-11-01 CR CR20120556A patent/CR20120556A/es unknown
- 2012-11-02 ZA ZA2012/08265A patent/ZA201208265B/en unknown
- 2012-11-02 DO DO2012000281A patent/DOP2012000281A/es unknown
- 2012-12-05 CO CO12221016A patent/CO6640262A2/es not_active Application Discontinuation
-
2015
- 2015-05-06 US US14/705,298 patent/US20150231265A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2566331A4 (en) | 2013-09-18 |
| PH12012502159A1 (en) | 2013-02-04 |
| WO2011140343A1 (en) | 2011-11-10 |
| AU2011247995A1 (en) | 2012-12-13 |
| US20110281901A1 (en) | 2011-11-17 |
| CL2012003075A1 (es) | 2013-03-08 |
| MA34286B1 (fr) | 2013-06-01 |
| AU2011247995B2 (en) | 2014-07-31 |
| ES2519615T3 (es) | 2014-11-07 |
| HK1175947A1 (en) | 2013-07-19 |
| US20150231265A1 (en) | 2015-08-20 |
| JP2013525501A (ja) | 2013-06-20 |
| ZA201208265B (en) | 2013-07-31 |
| BR112012028291A2 (pt) | 2015-09-15 |
| KR20130071434A (ko) | 2013-06-28 |
| CO6640262A2 (es) | 2013-03-22 |
| CN102970871A (zh) | 2013-03-13 |
| MX2012012837A (es) | 2013-01-24 |
| JP5835717B2 (ja) | 2015-12-24 |
| UY33367A (es) | 2011-10-31 |
| IL222751A0 (en) | 2012-12-31 |
| EP2566331B1 (en) | 2014-09-03 |
| EP2566331A1 (en) | 2013-03-13 |
| CR20120556A (es) | 2013-02-20 |
| DOP2012000281A (es) | 2013-05-31 |
| CA2798386A1 (en) | 2011-11-10 |
| SG185087A1 (en) | 2012-12-28 |
| TW201206908A (en) | 2012-02-16 |
| EA201291168A1 (ru) | 2013-06-28 |
| US20120028918A1 (en) | 2012-02-02 |
| PE20130217A1 (es) | 2013-03-21 |
| NZ603411A (en) | 2014-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR081364A1 (es) | Composiciones farmaceuticas de pazopanib y metodos para su elaboracion | |
| MX2020005942A (es) | Delgada pelicula oral con alta carga de agente activo. | |
| EA201291108A1 (ru) | Фармацевтические композиции в виде эмульсии с низким содержанием масла, содержащие прогестоген | |
| AR113034A2 (es) | Formulación líquida de un conjugado de la hormona del crecimiento humano de efecto prolongado | |
| CO6251369A2 (es) | Vacuna de influenza de emulsion de aceite en agua | |
| CL2008003762A1 (es) | Composicion concentrada en suspension acuosa para proteccion de cultivos, que comprende un compuesto activo y como agentes estabilizadores, un disperzante no ionico y un dsipersante anionico y agua; metodos para preparacion de dicha composicion y usos de la misma, para el cuidado de cultivos de interes. | |
| HRP20250382T1 (hr) | Farmaceutski pripravak koji sadrži karbetocin | |
| AR116874A2 (es) | Composición de glifosato para mezclas de tanque con dicamba con volatilidad mejorada | |
| BR112013003934A2 (pt) | depot de fosfolipídeos | |
| BR112015008186A2 (pt) | formulação de um anticorpo estável e de baixa viscosidade | |
| AR094012A1 (es) | Composiciones estables con peroxido para el cuidado oral | |
| CL2013003163A1 (es) | Composición transdermica de ibuprofeno, util en el tratamiento del dolor o la inflamacion. | |
| CO6270302A2 (es) | Formulaciones solidas de liberacion rapida que incluyen florfenicol y sales farmaceuticamente aceptables del mismo. | |
| AR065963A1 (es) | Solucion acuosa de peroxido de hidrogeno, proceso para su preparacion y su uso | |
| ES2720954T3 (es) | Formulaciones estabilizadas de estatina | |
| AR086651A1 (es) | Dentifrico de ion metalico con bajo contenido de agua | |
| PH12016502100A1 (en) | Liquid formulation comprising gm-csf neutralizing compound | |
| ES2509966T1 (es) | Composiciones que tienen concentraciones incrementadas de carboximetilcelulosa | |
| AR089269A1 (es) | Composiciones para el cuidado oral | |
| AR081520A1 (es) | Composicion farmaceutica que comprende una dispersion solida de tacrolimus en un vehiculo | |
| PH12015500864A1 (en) | Liquid formulation comprising gm-csf neutralizing compound | |
| MX383392B (es) | Mezclas y formulaciones que comprenden una sal de alquil amonio de ácido etilendiaminotetraacético (edta). | |
| AR096854A1 (es) | Composición farmacéutica para una liberación sostenida de lanreotide | |
| GT201400027A (es) | Acuosa suspensión concentrada que comprende un ácido sal de dodecilguanidina | |
| AR088067A1 (es) | Metodo para reducir la transpiracion y composiciones antitranspirantes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |